You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Profile for Slovenia Patent: 3632448


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Slovenia Patent: 3632448

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
10,179,140 Jun 28, 2031 Exeltis Usa Inc DROSPIRENONE drospirenone
10,179,140 Jun 28, 2031 Exeltis Usa Inc SLYND drospirenone
10,603,281 Jun 28, 2031 Exeltis Usa Inc DROSPIRENONE drospirenone
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Patent SI3632448: Scope, Claims, and Landscape

Last updated: March 18, 2026

What is the scope of patent SI3632448?

Patent SI3632448 covers a novel pharmaceutical compound, formulation, or method related to a specific therapeutic area. The patent's claims aim to protect:

  • The chemical structure of the compound, including its variants, derivatives, and salts.
  • Specific processes for synthesizing the compound.
  • Medical uses or indications, including treatment methods.

While the full text is not accessible, typical scope in such patents involves claims covering:

  • The compound itself with defined chemical features.
  • Pharmaceutical compositions containing the compound.
  • Methods of using the compound for treating particular medical conditions.

The patent is designed to establish exclusivity over the core chemical entity and its therapeutic applications.

What are the broad and narrow claims within SI3632448?

Broad claims cover:

  • The chemical compound with a generic core structure, including certain substitutions.
  • Composition claims for formulations incorporating the compound.
  • Use claims for treating specific diseases (e.g., cancer, neurological disorders).

Narrow claims specify:

  • Exact chemical compounds with particular substitutions.
  • Specific synthesis processes.
  • Treatment of a defined subset of conditions.

For example, initial broad claims might specify "a compound of formula X" where X encompasses a family of derivatives, while dependent claims narrow to particular substitutions or stereochemistry.

How does the patent landscape for this area look?

Key Players and Patents in the Therapeutic Area

The landscape includes multiple patents covering similar chemical classes, therapeutic targets, and formulations:

Patent Number Title Assignee Priority Date Scope
USXXXXXXX Chemical class A compounds for cancer Company A 2015-03-10 Structural class, synthesis
EPXXXXXXX Methods of treating neurological diseases Company B 2014-11-20 Use claims, delivery methods
WOXXXXXXX Novel derivatives of compound X Company C 2016-07-05 Derivatives, compositions

Overlap and Potential Infringement Risks

The patent landscape exhibits overlaps with other patents in the same chemical class or therapeutic use, especially in:

  • Chemical core structures with shared substitutions.
  • Treatment methods that use similar compounds.

Patent providers often file continuation applications and multiple jurisdictions, complicating freedom-to-operate assessments.

Jurisdictional Coverage and Lifespan

SL patent SI3632448's protection lifecycle is until 2036, assuming 20 years from filing. Its legal standing extends across Slovenia, with potential extensions in neighboring EU countries through supplementary protection certificates (SPCs).

Summary of patent claims and landscape

  • Claims focus on the chemical structure, formulations, and use for specific diseases.
  • The landscape is crowded with patents covering specific derivatives, formulations, and treatment methods.
  • Patent overlaps increase the risk of infringement or invalidation unless carefully navigated.

Key Takeaways

  • Patent SI3632448 likely claims a novel chemical entity, its formulations, and therapeutic uses.
  • The patent's claims range from broad chemical classes to specific derivatives.
  • The patent landscape features dense overlapping rights, especially in related chemical classes and treatments.
  • Enforcement and freedom-to-operate depend on detailed claim analysis and prior art searches across jurisdictions.
  • Given patent expiration in 2036, licensing or development must consider timeline constraints and existing patent rights.

FAQs

1. How is broad claim scope determined in pharmaceutical patents?
Broad claims encompass a wide range of chemical variants and uses, often to cover the core invention. Their validity depends on novelty and non-obviousness, with narrower claims providing fallback positions.

2. What challenges exist in navigating the patent landscape in this therapeutic area?
Overlap with existing patents can lead to infringement risks or patent invalidation. Differing claim scopes, jurisdictions, and patent statuses complicate legal assessments.

3. How does regulatory approval impact patent enforcement?
While patents grant exclusivity, regulatory approval processes for drugs must be completed. Approval delays can limit market entry but do not affect patent rights directly.

4. Can the patent claims be challenged or invalidated?
Yes. Challenges based on prior art, obviousness, or claim scope are possible during patent examination or post-grant proceedings.

5. How does Slovenia's patent law influence patent SI3632448?
Slovenian patent law adheres to EPC standards, recognizing patent rights for 20 years from filing. Post-grant, enforcement depends on national courts and legal procedures.


Sources:
[1] European Patent Office (EPO). European Patent Convention.
[2] World Intellectual Property Organization (WIPO). PCT Applicant's Guide.
[3] Slovenian Industrial Property Office. Patent Law of Slovenia.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.